Core Viewpoint - Nicox SA reported its financial results for the full year of 2024, highlighting a revenue increase and significant exceptional income from the sale of VYZULTA royalties, while also outlining future clinical milestones for its lead product, NCX 470 [1][4][6]. Financial Performance - Revenue for 2024 was €7.9 million, an increase from €6.9 million in 2023, including €3.0 million from VYZULTA royalties prior to their sale [4][6]. - Exceptional income in 2024 amounted to €13.7 million, primarily from the transfer of VYZULTA's future revenue stream to Soleus Capital, compared to €0.1 million in 2023 [6][8]. - Operating expenses decreased to €18.7 million in 2024 from €24.2 million in 2023 [5]. - The net loss for 2024 was €22.4 million, slightly higher than the €20.9 million loss in 2023, influenced by a non-cash impairment of €27.1 million related to intercompany receivables [9]. Cash Position and Financing - As of December 31, 2024, cash and cash equivalents were €10.5 million, down from €11.3 million in 2023, with funding expected to last into the fourth quarter of 2025 [10]. - Financial debt stood at €15.1 million, primarily from a bond financing agreement and a credit agreement related to COVID-19 support [11]. Future Milestones - Topline results from the Denali Phase 3 clinical trial for NCX 470 are expected in the third quarter of 2025, with additional results from the Whistler Phase 3b trial anticipated in May 2025 [6][7]. - The company is actively pursuing business development discussions for NCX 470, including potential partnerships in the U.S. [6][12]. Company Overview - Nicox SA is an international ophthalmology company focused on developing innovative solutions for ocular health, with NCX 470 as its lead program aimed at lowering intraocular pressure in glaucoma patients [13].